As a viable PET agent, an early phase I clinical trial is investigating [18F]-FTC-146 distribution in patients suffering from complex regional pain syndrome (CRPS) and sciatica to determine how S1R expression is altered in chronic pain states in humans (ClinicalTrials.gov, 2016). Here, TMBIM4 is linked to complex regional pain syndrome.